Add Yahoo as a preferred source to see more of our stories on Google. Spinogenix's first-in-class ALS treatment Spinogenix is progressing its lead candidate, SPG302, to a registrational trial ...

Neurizon hopes to initiate its regimen of the HEALEY-ALS trial in Q4 2025. Image credit: MAXIMUM ART / Shutterstock.com The US Food and Drug Administration (FDA) has released its clinical hold on ...

Half of the planned 200 ALS patients have joined Medicinova’s expanded access program evaluating the experimental drug MN-166.

U.S. clinical trials for ALS do not include enough non-white patients and women to reflect the disease's real-world prevalence, per a study.

Former NFL player and renowned ALS advocate Steve Gleason, founder of Answer ALS and Team Gleason, is Participant #1, providing his sample collected at home to initiate the study. He will be joined by ...

Management stated their operational readiness for the ENDURANCE trial, but initiation is contingent on securing financing. Lebovits explained, "Our ability to initiate the trial and remain listed on ...

This funding was awarded through the ALS Association's Hoffman ALS Clinical Trial Awards Program, which aims to accelerate the development of new ALS treatments ARLINGTON, Va., Dec. 4, 2025 ...

NEALS, the world's largest ALS research consortium, has selected the COYA 302 trial and it is now affiliated with NEALS as part of its mission to accelerate the development of new treatments for ...

CLEVELAND—Amyotrophic lateral sclerosis (ALS), known as Lou Gehrig’s disease, is an incurable neurological disorder affecting motor neurons—nerve cells in the brain and spinal cord that control ...

The US Food and Drug Administration (FDA) has released its clinical hold on Neurizon Therapeutics’ NUZ‑001, paving the way for its advancement to the HEALEY-ALS trial. The company’s lead drug in ...